BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9829842)

  • 1. Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-alpha.
    Hoffmann M; Schmidt M; Wels W
    Cancer Immunol Immunother; 1998 Nov; 47(3):167-75. PubMed ID: 9829842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
    Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors.
    Schmidt M; Maurer-Gebhard M; Groner B; Köhler G; Brochmann-Santos G; Wels W
    Oncogene; 1999 Mar; 18(9):1711-21. PubMed ID: 10208432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells.
    Bhat-Nakshatri P; Sweeney CJ; Nakshatri H
    Oncogene; 2002 Mar; 21(13):2066-78. PubMed ID: 11960379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis.
    Yamaoka T; Yan F; Cao H; Hobbs SS; Dise RS; Tong W; Polk DB
    Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11772-7. PubMed ID: 18701712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins.
    Jeschke M; Wels W; Dengler W; Imber R; Stöcklin E; Groner B
    Int J Cancer; 1995 Mar; 60(5):730-9. PubMed ID: 7860149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells.
    Egeblad M; Jäättelä M
    Int J Cancer; 2000 Jun; 86(5):617-25. PubMed ID: 10797281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
    Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
    Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor modulates epidermal growth factor receptor phosphorylation and kinase activity in human tumor cells. Correlation with cytotoxicity.
    Donato NJ; Gallick GE; Steck PA; Rosenblum MG
    J Biol Chem; 1989 Dec; 264(34):20474-81. PubMed ID: 2555361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
    Sliwkowski MX; Schaefer G; Akita RW; Lofgren JA; Fitzpatrick VD; Nuijens A; Fendly BM; Cerione RA; Vandlen RL; Carraway KL
    J Biol Chem; 1994 May; 269(20):14661-5. PubMed ID: 7514177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells.
    Fiddes RJ; Janes PW; Sanderson GM; Sivertsen SP; Sutherland RL; Daly RJ
    Cell Growth Differ; 1995 Dec; 6(12):1567-77. PubMed ID: 9019162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
    Chen X; Yeung TK; Wang Z
    Biochem Biophys Res Commun; 2000 Nov; 277(3):757-63. PubMed ID: 11062025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
    Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
    Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase.
    Adelsman MA; McCarthy JB; Shimizu Y
    Mol Biol Cell; 1999 Sep; 10(9):2861-78. PubMed ID: 10473632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
    Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
    Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
    J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
    Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
    Lewis GD; Lofgren JA; McMurtrey AE; Nuijens A; Fendly BM; Bauer KD; Sliwkowski MX
    Cancer Res; 1996 Mar; 56(6):1457-65. PubMed ID: 8640840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.